ðïž ç¬ç« è «çãã¥ãŒã¹ â 2026.07.01
ç¬ç«ã®è «çã»ããé¢é£ãã¥ãŒã¹ïŒè«æ èš6ä»¶
ðïž è «çã»ããé¢é£ãã¥ãŒã¹ â 2026.07.01
æ¬æ¥ 6ä»¶
1. 𧬠ç ç©¶ã»ç§åŠ
ç¬ã®éªšèè «ãå°å ããå æã®ã«ã®ã«ââã¿ãã倧ã1500äžãã«ã®åœéé£åã«åç»ãç¬ãšããã®æ²»çãåæã«åé²
ð 2026.06.04
ç±³ã¿ãã倧åŠã«ãã³ã°ã¹ç£å»åŠéšã®æ¯èŒè «çåŠè 2åïŒCheryl Londonå士ãHeather Gardnerå士ïŒããBreak Through Cancer財å£ã®ãDefying Osteosarcoma TeamLabãã«åç»ãããæ£è äž»å°ã®è²¡å£ãã1500äžãã«ã®åºè³ãåãã8ã€ã®äž»èŠç ç©¶æ©é¢ãã20åè¶ ã®ç ç©¶è ãçµéããå€å¹ŽåºŠãããžã§ã¯ãã§ãäž¡å士ã¯é£Œãç¬ã®éªšèè «ïŒosteosarcomaãæªæ§åºŠã®é«ãåçºæ§éªšè «çïŒã察象ãšããæ°èŠæ²»çã®èšåºè©Šéšãæ åœããã骚èè «ã¯ç±³åœã§å¹Žé2äž5000é è¶ ã®ç¬ã«çºçããäžæ¹ãããã§ã¯å°å ã»è¥å¹Žè ãäžå¿ã«å¹Žé1000äººæªæºã§ãç¬ã®çäŸæ°ã®å€ããšé²è¡ã®éãïŒå€ãã¯1ã2幎ã§èºè»¢ç§»ïŒãç ç©¶ãå éããããã¿ããããŒã ã¯æåã®4幎éã§4ã6ä»¶ã®ç¬åãèšåºè©Šéšãèšç»ãããªããããã€ãªãã·ãŒïŒè¡äžã®åŸªç°è «çDNAè§£æïŒãã²ãã è§£æããŒã¿ãããã®å°å 詊éšãžæ©æž¡ãããã
骚èè «ã®æšæºæ²»çã¯ãã®40幎éã»ãšãã©é²æ©ããŠãããã匷åãªååŠçæ³ãšå€ç§æè¡ãšããæ§å³ãç¶ããŠãããç¬ã¯å ç«ç³»ãæ£åžžãªãèªç¶çºçããã¢ãã«ããšããŠããŠã¹ããåªããç¬ã§åŸãç¥èŠã2030幎ãŸã§ã«å°ãªããšã2ä»¶ã®å°å 詊éšèšèšã«çŽæ¥åæ ãããèŠèŸŒã¿ã ã骚èè «ãçãããæç¬ïŒç¹ã«ãŽãŒã«ãã³ã»ã¬ããªãŒããŒãã°ã¬ãŒãã»ããŒã³ãªã©å€§åç¬ïŒã§ãè¶³ãåŒãããã»ç¹å®éšäœã®è «ããçã¿ãããå Žåã¯ãæ©æã«ãããã€ãå»ãè «çç§å°éå»ãžçžè«ããèšåºè©Šéšãžã®åå ã¯ç£å»åž«ãéããŠæ€èšã§ããã
𧬠ç ç©¶ã»ç§åŠ
2. ð å»çã»ããæ²»ç
ç¬ã§å®èšŒããã骚èè «ã¯ã¯ãã³ãOST-HER2ããããã®è»¢ç§»æ§éªšèè «ã§FDAæ¿èªå¯©æ»ãž
ð 2026.02.06
OS Therapies瀟ã¯ãèºè»¢ç§»ãå®å šåé€ãã骚èè «æ£è ã®åçºäºé²ã»é å»¶ãç®çãšããOST-HER2ïŒOST31-164ïŒã«ã€ããŠãç±³FDAãžã®ããŒãªã³ã°æ¹åŒã®çç©åŠçè£œå€æ¿èªç³è«ïŒBLAïŒãéå§ãããOST-HER2ã¯HER2ãçºçŸãããã现èã«å¯Ÿãå ç«åå¿ãèªå°ãããéºäŒåæ¹å€ãªã¹ããªã¢èãçšããå ç«çæ³ã§ãç¬ã®éªšèè «ã§ã¯ãã§ã«USDAïŒç±³èŸ²åçïŒã®æ¡ä»¶ä»ãæ¿èªãåããŠããããã第2bçžè©ŠéšïŒè©äŸ¡å¯èœäŸ36äŸïŒã§ã¯2å¹Žå šçåç75%ïŒæŽå²çå¯Ÿç §40%ãP<0.0001ïŒãéæãã12ã«æã®ç¡ã€ãã³ãçåãéæããæ£è ã§ã¯2å¹Žå šçåç100%ãšããçµæã ã£ããèšåºã¢ãžã¥ãŒã«ã¯2026幎3ææ«ãŸã§ã«æåºäºå®ã§ãFDAã®å€æã¯2026幎9æ30æ¥ãŸã§ã«èŠèŸŒãŸããŠããã
æ¬ä»¶ã¯ãæ¯èŒè «çåŠïŒcomparative oncologyïŒãã®æåäŸãšããŠæ³šç®ããããFDAã¯ç¬ã®éªšèè «è©Šéšãšãã第2bçžè©Šéšã暪æãããã€ãªããŒã«ãŒããŒã¿ã®å¯©æ»ã«é¢å¿ã瀺ããType DäŒè°ãäºå®ãããŠãããç¬ã®éªšèè «ã¯ãããšååã¬ãã«ã§é ·äŒŒããŠãããç¬ã§ã®å®èšŒãããã®åžå°ããæ²»çãåŸæŒãããæ§å³ã ãæç¬ã骚èè «ãšèšºæããã飌ãäž»ã¯ãHER2æšçå ç«çæ³ãå«ãææ°ã®éžæè¢ã«ã€ããŠè «çç§å°éå»ã«çžè«ãã
ð å»çã»ããæ²»ç
3. ð¥ å»çã»ããæ²»ç
åœç£ãã€ãåæPD-1æäœããç¬ã®å£è ã¡ã©ããŒãã§æç¶çãªæè «ç广ââ150é ã®å€æœèšè©Šéš
ð 2026.01.22
å±±å£å€§åŠã®äºé žå°åæ°ã»æ°Žéæä¹ææããšæ¥æ¬å šè¬å·¥æ¥ãªã©ã®ç ç©¶ã°ã«ãŒãããé²è¡ããç¬ã®å£è å æªæ§é»è²è «ïŒoral malignant melanomaïŒå£è ã¡ã©ããŒãïŒ150é ã察象ã«ãã€ãåæã€ãPD-1ã¢ãã¯ããŒãã«æäœãca-4F12-E6ãã®å®å šæ§ãšæå¹æ§ãè©äŸ¡ãã倿œèšååãèšåºè©Šéšã宿œããçµæãJournal for Immunotherapy of CancerèªïŒ2026幎1æ22æ¥ä»ïŒã«çºè¡šããã3mg/kgã2é±ããšã«éèæäžããçµæãå¥å¹çã¯14.7%ãæè¯å¥å¹çã¯16.7%ã§ãæ²»çé¢é£æå®³äºè±¡ã¯40.0%ïŒå€ãã¯ã°ã¬ãŒã1ã3ïŒã ã£ããããã«ãããŒã¹ã©ã€ã³ã®çœè¡çæ°ã»å¥œäžçæ°ã»CRPäžæã¯äºåŸäžè¯ãšé¢é£ãããã€ã¯ããµãã©ã€ãäžå®å®æ§ïŒMSIïŒãé«ãè «çã§ã¯å šçåæéãææã«å»¶é·ããïŒp=0.0168ïŒã
å£è ã¡ã©ããŒãã¯ç¬ã§éåžžã«äŸµè¥²æ§ãé«ãã確å®ãªå®å šå¯è§£ãåŸãããæ²»çã¯éãããŠãããå ç«ãã§ãã¯ãã€ã³ãé»å®³è¬ã§äžéšã®ç¬ã«æç¶çãªè «çå¶åŸ¡ãå¯èœã§ããããšãè£ä»ããããççããŒã«ãŒãMSIç¶æ ããå¹ããããåäœããèŠæ¥µããäºæž¬ãã€ãªããŒã«ãŒã«ãªãããç¹ãèšåºçã«éèŠã ãæç¬ã®å£ã®äžã«ãããã»åºè¡ã»å£èã»ãã ãã®å¢å ãªã©ãããå Žåã¯æ©æå蚺ããå ç«çæ³ã®é©å¿ã¯è «çç§å°éå»ãšçžè«ãã
ð https://pubmed.ncbi.nlm.nih.gov/41571458/
ð¥ å»çã»ããæ²»ç
4. ð± ç ç©¶ã»ç§åŠ
ç«ã®ä¹³ããããªã«ã¬ãã€ãã§åçŸã人ã®ãããšå ±éããé²è¡çµè·¯LMTK3/FADS2ãçºèŠââæ±äº¬èŸ²å·¥å€§
ð 2025.11.27
æ±äº¬èŸ²å·¥å€§åŠïŒå±±æ¬æŽæ°ãèŒäºéååææãäœã æšäžæææãïŒããå±±å£å€§åŠã»åé倧åŠãšã®å ±åç ç©¶ã§ãä¹³ããã«çœ¹æ£ããç«ã®è «ççµç¹ãã3次å ãªã«ã¬ãã€ãã®äœåºã«æåããScientific ReportsèªïŒ2025幎11æ22æ¥ä»ïŒã«çºè¡šãããç«ã®ä¹³ããïŒFBCïŒfeline breast cancerïŒã¯çŽ90%ãæªæ§ã§åçºçã¯çŽ80ã90%ãšéåžžã«é£æ²»æ§ã ããç ç©¶ããŒã ã¯32çäŸã®FBCãªã«ã¬ãã€ãã®äœè£œã«æåã忣è ç±æ¥ã®ãªã«ã¬ãã€ãã¯æããå€ã«å¯Ÿãåäœããšã«ç°ãªãæåæ§ã瀺ããè¬å€æåæ§è©äŸ¡ããŒã«ãšããŠæçšã§ããããšã瀺ããããRNAã·ãŒã¯ãšã³ã¹ã«ãããLMTK3/FADS2çµè·¯ã现è墿®ã»æµžæœ€ã»ã¢ãããŒã·ã¹ãä»ããŠFBCã®é²è¡ã«éèŠãªåœ¹å²ãæããããšã倿ããã
泚ç®ãã¹ãã¯ããã®LMTK3/FADS2çµè·¯ãããã®ä¹³ããçŽ°èæ ªãããä¹³ãããªã«ã¬ãã€ãã§ãåæ§ã«æ©èœããä¹³ããã®é²è¡ãšçžé¢ããŠããç¹ã ãç«ãšäººã®ä¹³ããã¯é¡äŒŒæ§ãå€ããæ¬ã¢ãã«ã¯æ°èŠæ²»çæšçã®æ¢çŽ¢ãšåç©ã»ããéã®ãã©ã³ã¹ã¬ãŒã·ã§ãã«ç ç©¶ã®äž¡é¢ã§æåŸ ããããç«ã®ä¹³è ºã®ãããã¯æªæ§ã®å¯èœæ§ãé«ããé¿åŠæè¡æªå®æœã®é«éœ¢ç«ã§ã¯ç¹ã«æ³šæãå¿ èŠãæ©æçºèŠã»æ©æã®å€ç§åé€ãäºåŸãå·Šå³ããããã宿çãªè§Šèšºãšãããã€ãå»ã§ã®ç¢ºèªãã
ð https://www.tuat.ac.jp/english/outline/disclosure/pressrelease/2025/20251127_01.html
ð± ç ç©¶ã»ç§åŠ
5. ð¥ å»çã»ããæ²»ç
ããªã³ãåç©ããã»ã³ã¿ãŒãææ°æŸå°ç·æ²»çè£ çœ®ãVarian Edgeããå°å ¥ââç¬ç«ã«é«ç²ŸåºŠã»çæéç §å°
ð 2026.04.22
ç±³ã³ãã©ãå·ç«å€§åŠããªã³ãåç©ããã»ã³ã¿ãŒïŒFACCïŒããææ°åã®ãªãã¢ã¢ã¯ã»ã©ã¬ãŒã¿ïŒçŽç·å éåšïŒãVarian Edgeããå°å ¥ãã2026幎4æ20æ¥ããæ²»çãéå§ããã第1å·æ£è ã¯éŒ»è è «çãšéã7æ³ã®ãŽãŒã«ãã³ã»ã¬ããªãŒããŒãCricketãã§ãéåžžåå²ç §å°18åã®æ²»çèšç»ãçµãŸãããæ¬è£ çœ®ã¯åšå²ã®æ£åžžçµç¹ãžã®åœ±é¿ãæããªããé«ç²ŸåºŠã«æŸå°ç·ãç §å°ã§ãã麻é ã»æ²»çæéã®ççž®ãç»åèªå°ã»æ²»çèšç»èœåã®åäžãå®çŸãããæŸå°ç·è «çç§ã®Tiffany Martinç§é·ã¯ã粟床ã»é床ã»é©å¿æ§ã«ãããŠç£å»æŸå°ç·è «çåŠã®å€é©çãªåé²ããšè¿°ã¹ãŠããã
æŸå°ç·æ²»çã¯éŒ»è è «çã»è³è «çã»éªšèè «ãªã©å€ç§åé€ãé£ããè «çã§éèŠãªéžæè¢ãšãªããé«ç²ŸåºŠãªå®äœæŸå°ç·æ²»çïŒSBRT/SRTïŒã¯è¿å¹Žã倧åŠç é¢ä»¥å€ã«ãæ®åãé²ã¿ãå°ççãªå¶çŽãç·©åããã€ã€ãããæç¬ã»æç«ãæè¡å°é£ãªéšäœã®è «çãšèšºæãããå ŽåãæŸå°ç·æ²»çã®é©å¿ã«ã€ããŠè «çç§å°éå»ã«çžè«ãã䟡å€ããããæ¬è£ çœ®ã¯è «ççç©åŠãæŸå°ç·ãšä»çæ³ã®äœµçšç ç©¶ã«ã掻çšãããæ¯èŒè «çåŠãéããŠããã®ããæ²»çã«ãéå ãããèŠèŸŒã¿ã ã
ð https://www.csuanimalcancercenter.org/2026/04/22/radiation-oncology-upgrade/
ð¥ å»çã»ããæ²»ç
6. 𧬠ç ç©¶ã»ç§åŠ
ç¬ç«ã®åºåœ¢è «çã«ããããªã«ã¬ãã€ãæ€æ»ãã§åå¥åæ²»çââæ±å€§ãèšåºè©Šéšãéå§
ð 2025.06.01
æ±äº¬å€§åŠå€§åŠé¢èŸ²åŠçåœç§åŠç ç©¶ç§ éå±åç©å»çã»ã³ã¿ãŒããç¬ãšç«ã®åºåœ¢è «çã«å¯ŸããçäŸããšã«æå¹ãªååæšçè¬ãç¹å®ããŠåå¥åæ²»çïŒãã¬ã·ãžã§ã³ã»ãªã³ã³ããžãŒïŒãè¡ãããã®ããããªã«ã¬ãã€ãã¹ã¯ãªãŒãã³ã°æ€æ»ããéçºãããã®æå¹æ§ãšå®å šæ§ãæ€èšŒããèšåºè©Šéšãéå§ãããæ¬è©Šéšã¯2025幎6æã«åã»ã³ã¿ãŒã®èšåºè©Šéšå§å¡äŒã§æ¿èªãããããã®æ€æ»ã§ã¯ãçæ€ãå€ç§æè¡ã§æ¡åããè «ççµç¹ãã3次å ã®ãªã«ã¬ãã€ãïŒæ£è ç±æ¥ã®ããè «çïŒãå¹é€ãã广ãæåŸ ã§ããåè£ãšãªãååæšçè¬ãéžã³åºããããã§å®éã«æäžãããã®å¹ãç®ãšå®å šæ§ã確ãããã
åŸæ¥ã®ããæ²»çã¯ãåã蚺æåãªãåãè¬ããåºæ¬ã ã£ãããå®éã«ã¯åãè «çã§ãåäœããšã«è¬ã®å¹ããããã倧ããç°ãªãããªã«ã¬ãã€ãã䜿ãã°æäžåã«ããã®åã«å¹ãè¬ããäºæž¬ã§ããç¡å¹ãªè¬ã«ããå¯äœçšãæéã®ãã¹ãæžãããå¯èœæ§ããããåæ§ã®ææ³ã¯ä»å€§åŠã§ãç¬ã®ç§»è¡äžç®çã»åç«è ºçã»èºçã»ã¢ãã¯ãªã³è ºçãªã©ã§å ±åãããŠãããæ¥æ¬çºã®åå¥åããå»çãçå®ã«åºããã€ã€ãããæç¬ã»æç«ãåºåœ¢è «çãšèšºæããæšæºæ²»çã§å¹æãä¹ããå Žåãããããå é²çæ€æ»ã»èšåºè©Šéšã®é©å¿ã«ã€ããŠè «çç§å°éå»ã倧åŠç é¢ã«çžè«ãã䟡å€ãããã
ð https://www.vm.a.u-tokyo.ac.jp/vmc/research/index.html
𧬠ç ç©¶ã»ç§åŠ
ðïž ç¬ç«è «çãã¥ãŒã¹ | all-i-need-are-dogs.blog

ã³ã¡ã³ããæ®ã